𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with gluthatione protection in patients with advanced head and neck cancer

✍ Scribed by Vittorio Gebbia; Roberto Valenza; Antonio Testa; Giuseppe Zerillo; Salvatore Restivo; Gianfranco Cupido; Federico Ingria; Giovanni Spadafora; Carmelo Barbaccia; Giuseppe Cannata; Calogero Cipolla; Nicola Gebbia

Book ID
112963637
Publisher
Springer US
Year
1992
Tongue
English
Weight
409 KB
Volume
9
Category
Article
ISSN
1357-0560

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Weekly 5-fluorouracil plus cisplatin for
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer
✍ Young Joo Lee; Chang Geol Lee; Byoung Chul Cho; Gwi Eon Kim; Hye Jin Choi; Eun C πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 160 KB

## Abstract ## Background. In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5‐fluorouracil (5‐FU) and cisplatin has increased acute toxicities as well as survival. Once‐weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we

Randomized phase III Study of 5-fluorour
Randomized phase III Study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer
✍ Dennie V. Jones; Roger J. Winn; Barry W. Brown; Lawrence B. Levy; Reginald P. Pu πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 501 KB

Background. Metastatic colorectal cancer is generally incurable. The most active regimen available, 5-fluorouracil(5-FU) and folinic acid (Leucovorin), produces response rates of approximately 25% to 30%. Methyl-lomustine is a nitrosourea with modest activity against colorectal cancer. A randomized